Literature DB >> 12142472

Bioterriorism: from threat to reality.

Ronald M Atlas1.   

Abstract

The fears and predictions of attacks with biological weapons, which were increasing at the close of the twentieth century, were transformed into reality not long after September 11, 2001, when several anthrax-laden letters were sent through the U.S. postal system. The attack challenged our medical preparedness and scientific understanding of the epidemiology of biothreat agents. It is fortunate that this was not a massive aerosol release that could have exposed hundreds of thousands. Rapid diagnoses and medical treatments limited casualties and increased survival rates, but tragically some individuals died of inhalational anthrax. Even as physicians tested new treatment regimes and scientists employed new ways of detecting anthrax and decontaminating the mail, new predictions were made for potentially even more devastating attacks with anthrax, smallpox, plague, tularemia, botulism, or hemorrhagic fever viruses. Fear gripped the nation. Law enforcement sought to find the villain(s) who sent the anthrax letters and to deter future bioterrorist attacks. The biomedical community began to seek new ways of protecting against such future threats of bioterrorism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142472     DOI: 10.1146/annurev.micro.56.012302.160616

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  32 in total

1.  Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Authors:  Hesham Taha; Stefan Dove; Jens Geduhn; Burkhard König; Yuequan Shen; Wei-Jen Tang; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

Review 2.  Current and developing technologies for monitoring agents of bioterrorism and biowarfare.

Authors:  Daniel V Lim; Joyce M Simpson; Elizabeth A Kearns; Marianne F Kramer
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

3.  Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.

Authors:  Mark R Deziel; Henry Heine; Arnold Louie; Mark Kao; William R Byrne; Jennifer Basset; Lynda Miller; Karen Bush; Michael Kelly; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5.

Authors:  Michael H Matho; Matt Maybeno; Mohammed Rafii-El-Idrissi Benhnia; Danielle Becker; Xiangzhi Meng; Yan Xiang; Shane Crotty; Bjoern Peters; Dirk M Zajonc
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  Validation of a pXO2-A PCR assay to explore diversity among Italian isolates of Bacillus anthracis strains closely related to the live, attenuated Carbosap vaccine.

Authors:  M Muscillo; G La Rosa; M Sali; E De Carolis; R Adone; F Ciuchini; A Fasanella
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Mouse model of oral infection with virulent type A Francisella tularensis.

Authors:  R KuoLee; X Zhao; J Austin; G Harris; J W Conlan; W Chen
Journal:  Infect Immun       Date:  2007-01-22       Impact factor: 3.441

7.  Whole-genome single-nucleotide-polymorphism analysis for discrimination of Clostridium botulinum group I strains.

Authors:  Narjol Gonzalez-Escalona; Ruth Timme; Brian H Raphael; Donald Zink; Shashi K Sharma
Journal:  Appl Environ Microbiol       Date:  2014-01-24       Impact factor: 4.792

8.  Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested.

Authors:  Ping-Jen Joe Chou; Catherine A Newton; Izabella Perkins; Herman Friedman; Thomas W Klein
Journal:  DNA Cell Biol       Date:  2008-12       Impact factor: 3.311

9.  Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.

Authors:  Yuequan Shen; Natalia L Zhukovskaya; Michael I Zimmer; Sandriyana Soelaiman; Pamela Bergson; Chyung-Ru Wang; Craig S Gibbs; Wei-Jen Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

10.  Nonenzymatic detection of bacterial genomic DNA using the bio bar code assay.

Authors:  Haley D Hill; Rafael A Vega; Chad A Mirkin
Journal:  Anal Chem       Date:  2007-10-10       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.